Skip to search formSkip to main contentSkip to account menu

Hu1D 10

Known as: Hu1D10 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
Apolizumab (Hu1D10), a humanized monoclonal anti- Human leukocyte antigen -DR β-chain antibody, mediates apoptosis of chronic… 
2006
2006
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRβ that demonstrated evidence for therapeutic… 
Highly Cited
2004
Highly Cited
2004
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.
The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR beta-chain-specific antibody that is currently in… 
2004
2004
Hu 1 D 10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
The 1D10 antigen is the target for Hu1D10 (apolizumab), a humanized HLA-DR -chain–specific antibody that is currently in clinical… 
2003
2003
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002
Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present… 
2002
2002
Enhanced killing of B lymphoma cells by granulocyte colony‐stimulating factor‐primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody
Summary. Antibody‐based approaches have become a novel treatment modality for lymphoma patients. Humanized 1D10 (Hu1D10… 
2002
2002
In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells
The humanized monoclonal antibody Hu1D10 (Remitogen™3;, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of… 
2002
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… 
Review
2002
Review
2002
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
Clinical activity of anti-CD20 monoclonal antibodies both in the unlabeled (rituximab [Rituxan; Genentech, Inc, South San… 
Review
2001
Review
2001
Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma.
Monoclonal antibodies (MAbs) have been used as therapeutic agents for many years. In 1997, Rituxan (IDEC-C2B8, rituximab… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)